drugset / Trial / NCT06207305
A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
To find the recommended dose of the drug paclitaxel that can be given intraperitoneally (given directly into the abdominal cavity) to participants with metastatic appendiceal adenocarcinoma.
Timeline
- Start
- 2024-01-30
- Primary completion
- 2028-01-02
- Completion
- 2028-01-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | — | Oral |
| Background | Dexamethasone | Small molecule | — | Oral |
| Background | Diphenhydramine | Unknown | — | Oral |
| Background | Famotidine | Other / unclassified | — | Oral |